Adjusting our regulatory framework to fit the COVID world

调整我们的监管框架以适应新冠疫情世界

• 批准号: 10024786
• 金额: $ 6.32万
• 依托单位: OXFORD HEARTBEAT LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10024786
• 关键词: Adjusting; our; regulatory; framework; fit

Our goal is to make cardiovascular surgeries more efficient and safe. This project develops the PreSize platform, a novel clinical decision-support solution that helps clinicians plan and rehearse stent placements inside blood vessels. Using cutting- edge computational modelling, we make the best use of available patient scans and stent device mechanics to accurately predict the behaviour of devices inside each patient's vessel configuration. This allows clinicians to optimise device selection, reducing the number of complications and the associated cost of stenting surgeries for hospitals and our society.We are a start-up company specifically created to bring this technology to hospitals. We currently run IUK Biomedical Catalyst Primer (BMC-P) project, and are incubated by The Royal Academy of Engineering. The results of our previous projects have received numerous awards, including the NHS Innovation Award 2017 from Health Enterprise East (HEE). We were named the "Best Healthcare Start-up of 2018" by WIRED magazine and were the national winner at the prestigious Medilink UK Healthcare Business Awards 2017\. We were selected to be part of the Digital Health London Accelerator (DHLA) programme, and previously one of the 6 startups selected globally by Philips Healthcare Accelerator, as well as featured in two Forbes articles as "founders striving to change the world" and "one of the new British start- ups to watch closely", two WIRED articles: "These are the healthcare start-ups you need to know about" and "From AI doctors to 3D X-rays, the future of healthcare is already here", and have been featured in The Times, Financial Times, etc.Our aim is to grow Oxford Heartbeat to be the leading provider of clinical decision support tools, to improve healthcare and define the medicine of tomorrow.

我们的目标是让心血管手术更高效、更安全。该项目开发了PreSize平台，这是一种新型的临床决策支持解决方案，可帮助临床医生计划和排练血管内支架放置。使用尖端的计算模型，我们最大限度地利用现有的患者扫描和支架设备机械，准确地预测每个患者血管配置内的设备的行为。这使临床医生能够优化设备选择，减少医院和社会支架手术的并发症数量和相关成本。我们是一家专门为将这项技术引入医院而创建的初创公司。我们目前正在进行IUK生物医学催化剂底漆(BMC-P)项目，并由皇家工程院孵化。我们之前项目的成果获得了许多奖项，包括2017年健康企业东部(Hee)颁发的NHS创新奖。我们被《连线》杂志评为2018年最佳医疗初创企业，并在著名的2017年Medilink UK医疗商业大奖中荣获全国冠军。我们被选为数字健康伦敦加速器(DHL)计划的一部分，之前是飞利浦医疗加速器在全球范围内选择的6家初创公司之一，并曾在《福布斯》的两篇文章中被选为“致力于改变世界的创始人”和“值得密切关注的新英国初创企业之一”，两篇连线文章：“这些是你需要了解的医疗初创公司”和“从人工智能医生到3D X光，医疗保健的未来已经在这里”，并曾在英国《泰晤士报》、英国《金融时报》、我们的目标是将牛津心跳发展成为临床决策支持工具的领先提供商，以改善医疗保健并定义未来的医学。